Tango Therapeutics, Inc. (TNGX)

NASDAQ: TNGX · Real-Time Price · USD

Compare

12.32

-0.23 (-1.83%)

At close: Feb 4, 2026, 4:00 PM EST

12.32

0.00 (0.00%)

After-hours: Feb 4, 2026, 4:04 PM EST

Tango Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	66.5	42.07	36.53	24.86	37.04	7.66
Revenue Growth (YoY)	53.29%	15.17%	46.93%	-32.89%	383.83%	-68.94%
Cost of Revenue	134	143.92	115.2	105.91	77.64	49.99
Gross Profit	-67.5	-101.85	-78.67	-81.05	-40.59	-42.34
Selling, General & Admin	42.84	43.75	35.5	30.03	17.6	9.87
Operating Expenses	42.84	43.75	35.5	30.03	17.6	9.87
Operating Income	-110.34	-145.6	-114.17	-111.07	-58.19	-52.2
Interest & Investment Income	5.76	7.89	6.62	1.46	0.5	0.11
Other Non Operating Income (Expenses)	6.01	7.61	5.94	1.49	-0.25	0.12
Pretax Income	-100.41	-130.09	-101.61	-108.12	-57.94	-51.97
Income Tax Expense	0.11	0.21	0.13	0.05	0.29	-
Net Income	-100.52	-130.3	-101.74	-108.18	-58.24	-51.97
Net Income to Common	-100.52	-130.3	-101.74	-108.18	-58.24	-51.97
Shares Outstanding (Basic)	111	109	95	88	62	32
Shares Outstanding (Diluted)	111	109	95	88	62	32
Shares Change (YoY)	2.50%	15.50%	7.69%	41.40%	94.50%	255.37%
EPS (Basic)	-0.91	-1.19	-1.08	-1.23	-0.94	-1.63
EPS (Diluted)	-0.91	-1.19	-1.08	-1.23	-0.94	-1.63
Free Cash Flow	-146.77	-132.26	-119.51	-116.77	-61.36	68.97
Free Cash Flow Per Share	-1.33	-1.21	-1.26	-1.33	-0.99	2.16
Gross Margin	-101.50%	-242.10%	-215.38%	-	-109.59%	-
Operating Margin	-165.91%	-346.09%	-312.57%	-446.79%	-157.09%	-681.82%
Profit Margin	-151.15%	-309.73%	-278.55%	-435.14%	-157.21%	-678.84%
Free Cash Flow Margin	-220.70%	-314.38%	-327.18%	-469.72%	-165.66%	900.84%
EBITDA	-107.91	-143.1	-111.76	-109.46	-57.29	-51.48
EBITDA Margin	-162.27%	-	-	-	-154.67%	-
D&A For EBITDA	2.42	2.5	2.42	1.61	0.9	0.72
EBIT	-110.34	-145.6	-114.17	-111.07	-58.19	-52.2
EBIT Margin	-165.91%	-	-	-	-157.09%	-
Revenue as Reported	66.5	42.07	36.53	24.86	37.04	7.66

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q